Trial · NCT04157517
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.1 mg/kg | 3 | |
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.2 mg/kg | 3 | |
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.4 mg/kg | 3 | |
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.75 mg/kg | 3 | |
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 1.0 mg/kg | 3 | |
| Overall Study | STARTED | Phase 1b, Dose Escalation: Modakafusp Alfa 1.5 mg/kg | 6 | |
| Overall Study | STARTED | Phase 2, Safety Lead-in: Modakafusp 1.0 mg/kg Alfa + Pembrolizumab 400 mg | 3 | |
| Overall Study | STARTED | Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg | 9 | |
| Overall Study | STARTED | Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg | 12 | |
| Overall Study | STARTED | Phase 2, Expansion, Cohort III: Modakafusp Alfa + Pembrolizumab | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.1 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.2 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.4 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 0.75 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 1.0 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 1b, Dose Escalation: Modakafusp Alfa 1.5 mg/kg | 0 | |
| Overall Study | COMPLETED | Phase 2, Safety Lead-in: Modakafusp 1.0 mg/kg Alfa + Pembrolizumab 400 mg | 0 | |
| Overall Study | COMPLETED | Phase 2, Expansion, Cohort I: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg | 0 | |
| Overall Study | COMPLETED | Phase 2, Expansion, Cohort II: Modakafusp Alfa 1.0 mg/kg + Pembrolizumab 400 mg | 0 | |
| Overall Study | COMPLETED | Phase 2, Expansion, Cohort III: Modakafusp Alfa + Pembrolizumab | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04157517/flow